Over 400 HR and benefits leaders, clinicians, and innovators came together for NEBGH's 15th Annual Health & Wellness Benefits Conference — on arguably the most electric day New York City has had in 53 years. The Knicks ticker tape parade was rolling down Broadway just blocks away, and the energy in the room matched it.
The theme was Powering Progress to Drive Change. The question driving every session: what actually moves the needle for your employees and your bottom line? Here's what we heard:
The messenger matters as much as the message.
Employers are one of the most trusted voices in their employees' lives — more trusted, in many cases, than a doctor they see once a year or a health plan they've never spoken to. That came up in vaccines, in behavioral health, in cancer navigation, and in AI. Whether it's encouraging someone to get a flu shot, flagging a mental health resource, or guiding an employee toward a better surgeon, the employer relationship is the channel that works. As one employer said plainly about vaccines: "It's not my job to tell people to get vaccinated. It's my job to make it as easy as possible for them to do so." The same logic applies across the board.
Coverage is not a strategy.
Session after session pushed past the question of whether something is covered to whether it's actually working. In behavioral health, session counts and satisfaction scores aren't enough — employers should be demanding validated clinical improvement data from their vendors. In women's health, a fertility benefit and a menopause solution sitting in separate corners of a benefits portal is not a strategy. In metabolic health, covering GLP-1s without pairing them with lifestyle support is an investment with an uncertain return. Cigna framed it well: "We're building a pathway, not just a gate." Access is the floor, not the ceiling.
Stop managing in silos.
One of the most consistent frustrations in the room: conditions that are deeply interconnected get managed as if they exist in isolation. Metabolic health is the clearest example — blood pressure, cholesterol, blood sugar, obesity, and cardiovascular risk all share a root cause, yet most programs address them branch by branch. Dr. Frank Dumont of Virta Health put it directly: our healthcare system was designed to treat branches, not roots, and that's why 93% of US adults are metabolically sick and getting sicker despite all the medications we prescribe. The same pattern shows up in women's health — fertility here, menopause there, pelvic health somewhere else — when what women need is a benefit that sees them as a continuous person with a continuous story. And in cancer, where survivorship care, mental health, and long-term treatment management are still treated as separate problems rather than one journey.
Data without action is just noise.
Employers have more data than ever. The question is what they're doing with it. In high-cost claims, the insight that landed hardest was the difference between observing a cost driver and identifying where there's real impactability — and building programs around those specific populations. In cancer, nearly every high-cost claimant can be traced back to a failure point early in the journey: a missed tumor marker, a delayed diagnosis, a wrong first step. In payment integrity, every inaccurate claim distorts your data and inflates your trend before you ever have a chance to act on it. The employers who are ahead aren't just collecting data — they're using it to get specific.
Prevention is still the best ROI — but only if you act early enough.
Early detection in cancer saves lives and cuts costs — an early-stage diagnosis is three to five times less expensive to treat than a late-stage one. In metabolic health, the opportunity to intervene before someone needs a GLP-1 — or before their prediabetes becomes type 2 diabetes — is real, and the tools exist. In women's health, pelvic pain that goes unaddressed doesn't go away — it becomes a $30,000 surgery that shows up on your claims as if it's something new. Menopause symptoms that are ignored cost $2 billion in lost productivity annually. The pattern is consistent: the kindest, cheapest version of care is always the earlier one.
AI is the connective tissue, not the answer.
AI ran through nearly every conversation of the day — in navigation, care access, payment integrity, member engagement, and clinical decision-making. The framing that stuck: AI isn't the thing, it's the context for all the other things. The cancer program, the MSK benefit, the navigation vendor — AI is what has the potential to make them work together for the individual, meeting each person at the right moment with the right nudge. But trust is the prerequisite. As one panelist put it: "Trust is earned in drops and lost in buckets." Employers evaluating AI vendors should be asking not just what the technology does, but what the organization's culture around privacy, safety, and human oversight actually looks like.
To everyone who joined us — thank you. This day only works because of the people in the room, and we are grateful for every conversation, every question, and every insight you brought with you. We'll see you on September 24th at our annual Pharmacy Benefits conference.
